Phaseline

Companies › Beeline Medicines

Beeline Medicines: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Immunology; next expected readout Apr 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Afimetoran (BLN-256)
Toll-like receptor 8 inhibitor; Toll-like receptor 7 inhibitor
TLR8, TLR7Phase 2Systemic Lupus Erythematosus; Cutaneous Lupus Erythematosus (CLE)Apr 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04895696Afimetoran (BLN-256)Phase 2Systemic Lupus ErythematosusImmunologyApr 2029
NCT07881120Afimetoran (BLN-256)Phase 2Cutaneous Lupus Erythematosus (CLE)ImmunologyApr 2030

Targets

TLR8 (1) TLR7 (1)

Companies with the same targets

Merck KGaA Eikon Therapeutics United Immunity HighField Biopharmaceuticals Ascendis Pharma Oncology Division Bolt Biotherapeutics Inimmune Solstice Oncology OX2 Therapeutics Primmune Therapeutics

Companies built like this

Calixis Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) Qifeng Zhang Topadur Pharma Leadingtac Pharmaceutical (Shaoxing)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.